Contact us

Investigational Product CDMO Companies
Clinical Contract Manufacturing Services

Your Trusted Partners for Clinical Contract Manufacturing and Development

Showing 139 facilities
Laboratorio REIG JOFRE, SA (TOLEDO PLANT)
Spain

Laboratorio REIG JOFRE, SA (TOLEDO PLANT)

LABORATORIO REIG JOFRE SA

Betalactam antibiotics (FDF) development and manufacturing state-of-the-art facilities.

MARKETS: EMA (EU), ANVISA (Brazil), ISP (Chile), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), INVIMA (Colombia), SFDA (Saudi Arabia), TGA (Australia)

REGION: APAC, MENA, LATAM, Europe, North America

COMPLIANCE: DIGEMID, ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), ECOVADIS, TGA (Australia GMP), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority), INVIMA, ISP (Chile BPM), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

BATCH SIZE: Large, Medium

USE: Human, Veterinary

BSL (Biological Safety Level): 1

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (J) Antiinfectives for systemic use

CONTROLLED SUBSTANCES: Lowest potential for abuse

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Laboratorios Grifols | Barcelona Plant
Spain

Laboratorios Grifols | Barcelona Plant

Grifols International

Sterile manufacturing solutions (small molecules) in flexible bags and vials.

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), ANMAT (Argentina), MFDS (South Korea), TGA (Australia)

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (M) Musculoskeletal system, (N) Nervous system, (A) Digestive tract and metabolism

CONTROLLED SUBSTANCES: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

White Raven - Legiapark
Belgium

White Raven - Legiapark

White Raven

Fill and finish site dedicated to GMP Formulation and the Aseptic filling of Sterile Liquid Injectables.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: EMA (EU)

REGION: Europe

USE: Human

BSL (Biological Safety Level): 1, 2

SERVICES: Manufacturing services, Packaging

BATCH SIZE: Small, Medium

COMPLIANCE: EMA (EU GMP)

CATEGORY / PRODUCT: BIOLOGICS, FDF / DRUG PRODUCTS

Laboratorio REIG JOFRE, SA (BARCELONA PLANT)
Spain

Laboratorio REIG JOFRE, SA (BARCELONA PLANT)

LABORATORIO REIG JOFRE SA

Injectable (lyo and liquid) and Liquid manufacturing facilities.

BSL (Biological Safety Level): 3, 1, 2

MARKETS: EMA (EU), PMDA (Japan), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MHRA (UK), INVIMA (Colombia), MFDS (South Korea), TGA (Australia)

REGION: Europe

BATCH SIZE: Large, Medium

USE: Human, Veterinary

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (D) Dermatologicals, (J) Antiinfectives for systemic use, (N) Nervous system, (R) Respiratory system, (A) Digestive tract and metabolism

CONTROLLED SUBSTANCES: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

COMPLIANCE: PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), ECOVADIS, INVIMA, ISP (Chile BPM), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Sylentis
Spain

Sylentis

Sylentis

Oligonucleotide manufacturer.

COMPLIANCE: ICH, FDA (cGMP), ISO, EMA (EU GMP), World Health Organization (GMP / HACCP)

MARKETS: EMA (EU), FDA (USA)

REGION: Europe

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CATEGORY / PRODUCT: OLIGONUCLEOTIDES

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

VIVEbiotech
Spain

VIVEbiotech

VIVEbiotech

Your leading GMP-certified CDMO exclusively dedicated to the production of lentiviral vectors.

MARKETS: EMA (EU), FDA (USA), MHRA (UK)

REGION: Europe

COMPLIANCE: FDA (cGMP), French Service-Public (CIR), EMA (EU GMP), MHRA (UK GMP)

BATCH SIZE: Large, Small, Medium

USE: Human

BSL (Biological Safety Level): 1, 2

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

CATEGORY / PRODUCT: BIOLOGICS

Viswa Laboratories Pvt Ltd
India

Viswa Laboratories Pvt Ltd

Viswa Laboratories Private Limited

CRAMS/CDMO, APIs, Intermediates and specialty chemicals.

MARKETS: EMA (EU), NMPA (China), ANVISA (Brazil), Russian Health Authorities, CDSCO (India)

REGION: APAC

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

BSL (Biological Safety Level): 1, 2

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

SERVICES: Development services, Manufacturing services

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (D) Dermatologicals, (J) Antiinfectives for systemic use, (M) Musculoskeletal system, (R) Respiratory system

CONTROLLED SUBSTANCES: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

COMPLIANCE: World Health Organization (GMP / HACCP)

Pharmaron API Commercial Synthesis Shaoxing (China)
China

Pharmaron API Commercial Synthesis Shaoxing (China)

Pharmaron

Commercial API Small Molecules /Peptides Synthesis.

THERAPEUTIC AREAS OF EXPERTISE (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (V09-10) Radiopharmaceuticals, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: NMPA (China), FDA (USA)

REGION: APAC

COMPLIANCE: FDA (cGMP), ISO, NMPA (China GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services

Pharmaron API Commercial Synthesis Cramlington (UK)
United Kingdom

Pharmaron API Commercial Synthesis Cramlington (UK)

Pharmaron

Commercial API Small Molecules Synthesis.

THERAPEUTIC AREAS OF EXPERTISE (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), TGA (Australia)

REGION: Europe

COMPLIANCE: FDA (cGMP), PMDA/MHLW (Japan GMP), TGA (Australia GMP), EMA (EU GMP), Health Canada (Canada GMP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

Pharmaron API Commercial Synthesis Coventry (US)
United States

Pharmaron API Commercial Synthesis Coventry (US)

Pharmaron

Commercial API Small Molecules Synthesis.

THERAPEUTIC AREAS OF EXPERTISE (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), MHRA (UK), MFDS (South Korea), TGA (Australia)

COMPLIANCE: FDA (cGMP), ISO, ECOVADIS

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

SERVICES: Development services, Manufacturing services

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

REGION: North America

HIPRA BIOTECH SERVICES | Amer
Spain

HIPRA BIOTECH SERVICES | Amer

HIPRA Biotech Services

End-to-end internal capabilities from cell line development to commercial manufacturing.

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia)

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

BSL (Biological Safety Level): 1, 2

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: BIOLOGICS, FDF / DRUG PRODUCTS

BAG Health Care
Germany

BAG Health Care

BAG Health Care GmbH

Parenteral F&F provider for vials in small to mid sized batches.

MARKETS: EMA (EU), MHRA (UK), TGA (Australia)

REGION: Europe

USE: Human, Veterinary

BSL (Biological Safety Level): 1

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

BATCH SIZE: Small, Medium

COMPLIANCE: EMA (EU GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

More facilities on the network

Register to unlock the full catalog with contact details and locations.

+73 more facilities

Create free account

The development of an investigational product requires precision, regulatory compliance, and efficiency to ensure the success of clinical trials. From early-stage development to large-scale clinical manufacturing, pharmaceutical and biotech companies rely on specialized investigational product Contract Development and Manufacturing Organizations (investigational product CDMOs) to fulfill regulatory requirements and accelerate time to market.

How to Choose an Investigational Product CDMO

Selecting the right investigational product CDMO is key to a smooth clinical trial progression. Look for a partner with expertise in Good Manufacturing Practice (GMP) compliance, flexible production capabilities, and experience in managing Investigational Medicinal Products (IMPs) across multiple therapeutic areas.

A robust clinical manufacturing CDMO should offer comprehensive end-to-end support, including formulation development, small-batch manufacturing, clinical packaging, and regulatory consulting. Scalability is also essential to ensure a seamless transition from early-phase trials to commercial production.

Key Services Offered by Clinical Manufacturing CDMOs

Optimizing dosage forms through Formulation and Process Development: Investigational product CDMOs possess expertise in optimizing formulations for investigational products across diverse dosage forms.

Supplying phase-specific trials with GMP Clinical Manufacturing: Small-scale production for Phase I–III trials with strict regulatory compliance and quality assurance.

Securing study integrity via Packaging and Labeling: Clinical trial supply packaging, randomization, and blinding to meet study requirements.

Navigating global filings with Regulatory Support: Clinical manufacturing CDMOs provide assistance with Investigational New Drug (IND) applications, Clinical Trial Applications (CTAs), and global regulatory compliance.

Assuring drug consistency via Analytics and Stability Testing: Comprehensive quality control testing to ensure product consistency and safety.

Advantages of Partnering with Clinical CDMOs

Ensuring compliance standards with Regulatory Compliance: Investigational product CDMOs ensure adherence to EMA, FDA, and other international regulatory standards for clinical manufacturing.

Adapting batch volumes via Flexible and Scalable Production: Clinical CDMOs have the capacity to manage small clinical batches with a seamless scale-up toward commercial manufacturing.

Utilizing high-containment suites in Advanced Facilities: State-of-the-art technology for aseptic processing, high-containment manufacturing, and specialized pharmaceutical formulations.

Accelerating trial timelines for Speed to Market: Streamlined processes to minimize delays and support efficient clinical trial execution.

Streamlining development workflows through End-to-End Support: From formulation development to final packaging, clinical manufacturing CDMOs offer complete solutions for investigational product success.

Investigational Product CDMO Companies

Some of the top investigational product CDMO companies include:

HIPRA BIOTECH SERVICES: Comprehensive capabilities spanning from cell line development to commercial manufacturing. [See CDMO profile]

Skyepharma: Specialists in the development and supply of oral technologies for the pharmaceutical, biotech, and consumer health industries. [See CDMO profile]

Ophtapharm, a Sentiss Company: Ophthalmic and otic production (solutions, suspensions, emulsions, ointments, and gels) in FDA-approved facilities for investigational products. [See CDMO profile]

CARBOGEN AMCIS: Development of highly potent APIs and small-scale cGMP manufacturing, featuring chromatography and lyophilization capabilities. [See CDMO profile]

Sichuan Huiyu Pharmaceuticals Co., Ltd: Manufacturing and formulation facilities supported by a core R&D center for the development of APIs, finished dosage forms, and investigational products. [See CDMO profile]

AdhexPharma SAS: CDMO specialized in transdermal patches and oromucosal films. [See CDMO profile]

Sylentis: Manufacturing of oligonucleotides for therapeutic applications. [See CDMO profile]

Apeloa Pharmaceutical Co., Ltd: Development and manufacturing services for APIs, intermediates, and registered starting materials. [See CDMO profile]

Glatt Pharmaceutical Services GmbH Co. & KG: cGMP CDMO providing comprehensive services in complex solid oral formulations. [See CDMO profile]

Lukas Heil-Betriebsstätte: High-performance plant for sterile and aseptic production, specializing in glass ampoules and investigational products. [See CDMO profile]

Darnytsia Kyiv: CMO featuring advanced facilities, rigorous quality controls, and expert teams for reliable, compliant solutions. [See CDMO profile]

Basic Pharma Manufacturing: Analytical services and regulatory support tailored to specific needs, adhering to all applicable quality guidelines. [See CDMO profile]

Adragos Pharma: Over a century of experience offering customer-centric pharmaceutical manufacturing and support for investigational products. [See CDMO profile]

Cellex Cell Professionals: Advanced Therapy (CGT) CDMO with a cell manufacturing plant and biological material collection center for investigational products. [See CDMO profile]

Rodon Biologics: Development of biopharmaceutical products for third parties, including batches for preclinical and clinical studies. [See CDMO profile]

White Raven: GMP facility dedicated to the aseptic fill & finish of sterile injectables and investigational products. [See CDMO profile]

BAG Health Care: Parenteral manufacturing (fill-finish) of vials in small and medium batches, including investigational products. [See CDMO profile]

Cambrex: Early-stage small molecule drug development within integrated drug substance and finished product facilities. [See CDMO profile]

Actylis Eugene: Discovery, development, cGMP, and commercial manufacturing of chemical processes. [See CDMO profile]

Aenova Group: Center of excellence for conventional solids, clinical services, and investigational products. [See CDMO profile]

HISTOCELL S.L: Development and manufacturing of cell therapies (iPSCs, MSCs, exosomes, secretomes) as well as medical devices and dermocosmetics. [See CDMO profile]

53Biologics Production Plant: Production of biologics from DNA to proteins, covering preclinical phases through cGMP manufacturing. [See CDMO profile]

Liof Pharma: Clinical CDMO specialized in aseptic manufacturing and lyophilization of biologics and injectables. [See CDMO profile]

Cultiply: CDMO for recombinant proteins, enzymes, DNA, and other bioderived products. [See CDMO profile]

BDI biotech: R&D partner in strain and bioprocess development, scale-up, and batch production. [See CDMO profile]

Cenexi: Clinical CDMO specialized in highly potent sterile injectables, particularly oncology. [See CDMO profile]

I+Med: Development and manufacturing of dosage forms with controlled release technologies. [See CDMO profile]

ASCIL Biopharm: GMP facility equipped for R&D and pharmaceutical development with a pilot plant for technical and clinical batches of sterile products. [See CDMO profile]

VIVUNT: Clinical CDMO for investigational sterile oncology drugs. [See CDMO profile]

Grifols: Clinical manufacturing of bags and vials for multiple applications. [See CDMO profile]

Lannett CDMO: Primary manufacturing site in Seymour, Indiana, offering capabilities for oral solids and liquid forms. [See CDMO profile]

Viswa: CRAMS/CDMO for APIs, intermediates, and specialty chemicals. [See CDMO profile]

FAES FARMA: Development and manufacturing of investigational products for human use. [See CDMO profile]

Pharmaron: Commercial facility for small molecules (RSM/APIs). [See CDMO profile]

Shilpa Biologicals: End-to-end CDMO from cell line development to GMP manufacturing, formulation, analytics, and fill-finish. [See CDMO profile]

Mabion: Fully integrated clinical CDMO for biotherapeutics, including monoclonal antibodies and recombinant proteins. [See CDMO profile]

Reig Jofre: Production of injectables (lyophilized and liquid) and non-sterile liquids. [See CDMO profile]

VIVEbiotech: GMP CDMO specialized exclusively in lentiviral vectors. [See CDMO profile]

Let MAI CDMO Help You Find the Right Clinical Manufacturing Partner

Navigating the complexities of investigational product development and clinical manufacturing can be challenging. MAI CDMO simplifies the process by connecting you with trusted clinical CDMOs specialized in GMP-compliant clinical trial production.

Our team ensures that your project aligns with the capabilities of leading clinical manufacturing providers, facilitating a seamless path from early-stage development to market approval.

Contact us today to find the best investigational product CDMO and accelerate your clinical manufacturing journey with a reliable partner.